Avidity Biosciences, Inc. (RNA)
| Market Cap | 6.01B |
| Revenue (ttm) | 10.73M |
| Net Income (ttm) | -455.74M |
| Shares Out | 143.65M |
| EPS (ttm) | -3.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,216,989 |
| Open | 40.07 |
| Previous Close | 40.06 |
| Day's Range | 39.83 - 41.92 |
| 52-Week Range | 21.51 - 56.00 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 69.81 (+66.97%) |
| Earnings Date | Nov 6, 2025 |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystro... [Read more]
Financial Performance
In 2024, Avidity Biosciences's revenue was $10.90 million, an increase of 13.99% compared to the previous year's $9.56 million. Losses were -$322.30 million, 51.9% more than in 2023.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price target is $69.81, which is an increase of 66.97% from the latest price.
News
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
Avidity Biosciences remains a Strong Buy for me, driven by Del-zota's promising data in targeting Duchenne Muscular Dystrophy exon 44 skipping patients. Del-zota showed sustained 25% dystrophin produc...
Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.
Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)
Avidity Biosciences, Inc. (NASDAQ:RNA) Discusses on Redefining the Treatment of Duchenne Muscular Dystrophy Conference Call September 10, 2025 8:00 AM EDT Company Participants Katja Lange - Senior VP...
Avidity Biosciences Announces Proposed Public Offering of Common Stock
SAN DIEGO , Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and ...
Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Avidity Biosciences, Inc. (NASDAQ:RNA) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Kathleen Gallagher - Chief Program Officer Michael Ma...
Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript
Avidity Biosciences, Inc. (NASDAQ:RNA) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Sarah Boyce - President, CEO & Director Steven Hughes - Chief Medic...
Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Avidity Biosciences, Inc. (NASDAQ:RNA) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Michael MacLean - Chief Financial Officer Kathleen Gallag...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned de...
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
-- Topline data readout from HARBOR study anticipated in Q2 2026 -- -- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to po...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
-- On track for planned BLA submission for del-zota at year end 2025 -- SAN DIEGO , July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to deli...
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D.
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and signif...
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD ™ study of del-brax 2...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co...
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports firs...
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Con...
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceut...
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initi...
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts Plan to pr...
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present topline d...